Rapport Therapeutics, Inc. (NASDAQ: RAPP) Stock Information | RedChip
Image

ASK REDCHAT ANYTHING ABOUT RAPPORT THERAPEUTICS, INC.

Rapport Therapeutics, Inc. (NASDAQ: RAPP)
Listen to this Section


$37.34
+0.3410 ( +0.92% ) 77.7K

Rapport Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovery and development of transformational small-molecule medicines for patients suffering from central nervous system disorders. Its foundational science has elucidated the complexities of neuronal receptor biology and enables the company to map and target certain neuronal receptor complexes. Neuronal receptors are complex assemblies of proteins, comprising receptor principal subunits and their receptor-associated proteins (RAPs), the latter of which play crucial roles in regulating receptor expression and function.

Market Data


Open $37.34
Previous Close $37.00
Volume 77.7K
Market Cap $1.77B
Day Range $36.98 - $38.45
52 Week Range $10.51 - $42.27
Shares Outstanding 47.83M
Change % +0.92%
Net Change ▲ 0.3410
Insider Ownership -0.01%
Exchange NASDAQ
SectorMiscellaneous
IndustryNone
IPO Year2024
CountryUnited States
UnderwriterGoldman Sachs, Jefferies, TD Cowen, Stifel, more

Insider Ownership Transactions

Total Amount Purchased: -3,756,034.00

Date Type Amount Purchased Purchaser
2025-09-15 Buy 28284.00 PAUL STEVEN M
2025-09-15 Buy 20400.00 Huber Reid M
2025-09-15 Buy 20400.00 Huber Reid M
2025-09-15 Buy 20400.00 Huber Reid M
2025-09-11 Buy 3500.00 Young Wendy B.
2024-07-03 Buy 3538.00 HEALY JAMES
2024-06-10 Sale -123818.00 Galer Bradley S.
2024-06-10 Sale -3728738.00 ARCH Venture Partners XII, LLC

SEC Filings


Form Type Description Pages Date
10-q Quarterly Reports 67 Nov 06, 2025
8-k 8K-related 12 Nov 06, 2025
4 Insider transactions 1 Oct 16, 2025
4 Insider transactions 1 Oct 16, 2025
4 Insider transactions 1 Sep 19, 2025
4 Insider transactions 1 Sep 17, 2025
4 Insider transactions 1 Sep 15, 2025
4 Insider transactions 1 Sep 15, 2025
4 Insider transactions 1 Sep 11, 2025
4 Insider transactions 1 Sep 10, 2025

Latest News


× Before browsing our site, please accept our cookies policy